Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

2 Nov 2012

Abstract excerpt

BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype Ad26 vector-based human immunodeficiency virus (HIV) vaccine in humans. METHODS: Sixty Ad26-seronegative, healthy, HIV-uninfected subjects were enrolled in a randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study. Five groups of 12 subjects received 10(9)-10(11) vp of the Ad26-EnvA vaccine (N =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23125444
DOI: 10.1093/infdis/jis670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)PMID 23125444Read ↗

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targetsSemantic proximity Read ↗

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccineSemantic proximity Read ↗

Human adenovirus type 26 basic biology and its usage as vaccine vectorSemantic proximity Read ↗

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trialSemantic proximity Read ↗

Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B <i>gag</i> Vaccines in Healthy AdultsSemantic proximity Read ↗

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2Semantic proximity Read ↗

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 YearsSemantic proximity Read ↗

New Insights on Adenovirus as Vaccine VectorsSemantic proximity Read ↗

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity Read ↗

Adenovirus Vector-Based Vaccines for Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Novel adenovirus vector-based vaccines for HIV-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.